ImmunityBio Plans Expansion in Turkey Amid AI Manufacturing Advances
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Global Expansion Plans: Founder Patrick Soon-Shiong hinted at ImmunityBio's global expansion, particularly in Turkey, indicating an acceleration of its international commercialization strategy, despite a 5% decline in stock price to $8.11 on Monday.
- AI Manufacturing Robot Nears Completion: The company's AI-driven NK cell manufacturing robot, internally called “Leonardo,” is nearing completion and is expected to mass-produce natural killer cells, significantly enhancing ImmunityBio's production capabilities and competitive position in cancer immunotherapy.
- International Market Dynamics: Soon-Shiong's inspection of the manufacturing robot in Italy coincides with ImmunityBio securing approvals for its immunotherapy candidate Anktiva in multiple countries, showcasing the company's expansion momentum in the Middle East and North Africa, which boosts investor confidence in its international growth.
- Ongoing FDA Review: ImmunityBio's Anktiva is under FDA review for its supplemental biologics license application, with long-term data showing that 58.2% of patients remained cancer-free after 12 months, which could drive further development in the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.110
Low
5.00
Averages
7.33
High
9.00
Current: 8.110
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Immunotherapy Approved in Saudi Arabia
- Saudi FDA Approval: ImmunityBio's Quilt 3005 immunotherapy has received approval from the Saudi FDA, enhancing the company's reputation in the Middle East and providing strong support for its global expansion strategy.
- FDA Review Dynamics: Investors are closely monitoring the FDA's review of ImmunityBio's resubmitted BLA for Anktiva plus BCG, with data indicating that 58.2% of patients remained cancer-free after 12 months, which could significantly impact future market performance.
- Stock Price Volatility: Although IBRX shares slid over 1% in Monday trading, they surged 20% last week, reflecting ongoing market interest and potential confidence in the company's immunotherapy.
- Global Expansion Plans: ImmunityBio's launch of Anktiva in Saudi Arabia and partnerships with local biopharma firms signify its expansion in the Middle East and North Africa, further solidifying its competitive position in the global market.
See More
ImmunityBio Faces Class Action Lawsuit and FDA Warning
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 26, 2026, highlighting significant legal risks for the firm.
- FDA Warning Letter: On March 24, 2026, the FDA publicly disclosed a warning letter to ImmunityBio, asserting that the company continues to promote its bladder cancer drug Anktiva in a misleading manner despite prior warnings, indicating serious compliance issues.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by 21.12% to close at $7.41 per share on March 24, 2026, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, is known for advocating the rights of victims of securities fraud, suggesting that this lawsuit could attract broader legal scrutiny.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action lawsuit for failing to disclose that server sales to Chinese companies violated U.S. export control laws, with investor losses exceeding $50,000 and a lead plaintiff deadline of May 26, 2026, which could significantly impact the company's reputation and stock price.
- ImmunityBio Issues: ImmunityBio, Inc. (NASDAQ:IBRX) is being sued for materially overstating Anktiva's capabilities, with investor losses during the class period from January 19 to March 24, 2026, potentially affecting future financing and market trust, with a lead plaintiff deadline of May 26, 2026.
- Pinterest Revenue Decline: Pinterest, Inc. (NYSE:PINS) faces a class action lawsuit for not disclosing risks of declining advertising revenues, with investor losses from February 7, 2025, to February 12, 2026, possibly leading to company restructuring, and a lead plaintiff deadline of May 29, 2026.
- New Era Energy Fraud Allegations: New Era Energy & Digital, Inc. (NASDAQ:NUAI) is being sued for falsely reporting progress on its Texas data center project and involvement in fraudulent schemes, with investor losses from November 6, 2024, to December 29, 2025, potentially affecting financial stability, and a lead plaintiff deadline of June 1, 2026.
See More
ImmunityBio Shareholder Files Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead biologic product, ANKTIVA, which may have led to investor losses.
- Lawsuit Details: Investors who acquired ImmunityBio shares during the specified period and suffered losses can file to serve as lead plaintiff by May 26, 2026, allowing them to represent other class members in the litigation and protect their interests.
- Fee Arrangement: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its expertise and influence in securities litigation.
See More
ImmunityBio Plans Expansion in Turkey Amid AI Manufacturing Advances
- Global Expansion Plans: Founder Patrick Soon-Shiong hinted at ImmunityBio's global expansion, particularly in Turkey, indicating an acceleration of its international commercialization strategy, despite a 5% decline in stock price to $8.11 on Monday.
- AI Manufacturing Robot Nears Completion: The company's AI-driven NK cell manufacturing robot, internally called “Leonardo,” is nearing completion and is expected to mass-produce natural killer cells, significantly enhancing ImmunityBio's production capabilities and competitive position in cancer immunotherapy.
- International Market Dynamics: Soon-Shiong's inspection of the manufacturing robot in Italy coincides with ImmunityBio securing approvals for its immunotherapy candidate Anktiva in multiple countries, showcasing the company's expansion momentum in the Middle East and North Africa, which boosts investor confidence in its international growth.
- Ongoing FDA Review: ImmunityBio's Anktiva is under FDA review for its supplemental biologics license application, with long-term data showing that 58.2% of patients remained cancer-free after 12 months, which could drive further development in the U.S. market.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding its immunotherapy Anktiva, with the class period spanning from January 19, 2026, to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that promotional claims made in a podcast and TV ad about Anktiva were false or misleading, resulting in a more than 21% drop in the company's stock price that day, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging those who suffered significant losses during the class period to submit their losses for potential inclusion in the class action.
- Public Health Impact: The FDA warned that the pervasive misleading efficacy claims across various promotional materials could pose serious public health risks, as they grossly misrepresent the benefits of Anktiva, raising concerns about the company's accountability and transparency.
See More
ImmunityBio's Immunotherapy Approved in Saudi Arabia
- Saudi FDA Approval: ImmunityBio's Quilt 3005 immunotherapy has received approval from the Saudi FDA, enhancing the company's reputation in the Middle East and providing strong support for its global expansion strategy.
- FDA Review Dynamics: Investors are closely monitoring the FDA's review of ImmunityBio's resubmitted BLA for Anktiva plus BCG, with data indicating that 58.2% of patients remained cancer-free after 12 months, which could significantly impact future market performance.
- Stock Price Volatility: Although IBRX shares slid over 1% in Monday trading, they surged 20% last week, reflecting ongoing market interest and potential confidence in the company's immunotherapy.
- Global Expansion Plans: ImmunityBio's launch of Anktiva in Saudi Arabia and partnerships with local biopharma firms signify its expansion in the Middle East and North Africa, further solidifying its competitive position in the global market.
See More
ImmunityBio Faces Class Action Lawsuit and FDA Warning
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 26, 2026, highlighting significant legal risks for the firm.
- FDA Warning Letter: On March 24, 2026, the FDA publicly disclosed a warning letter to ImmunityBio, asserting that the company continues to promote its bladder cancer drug Anktiva in a misleading manner despite prior warnings, indicating serious compliance issues.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by 21.12% to close at $7.41 per share on March 24, 2026, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, is known for advocating the rights of victims of securities fraud, suggesting that this lawsuit could attract broader legal scrutiny.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action lawsuit for failing to disclose that server sales to Chinese companies violated U.S. export control laws, with investor losses exceeding $50,000 and a lead plaintiff deadline of May 26, 2026, which could significantly impact the company's reputation and stock price.
- ImmunityBio Issues: ImmunityBio, Inc. (NASDAQ:IBRX) is being sued for materially overstating Anktiva's capabilities, with investor losses during the class period from January 19 to March 24, 2026, potentially affecting future financing and market trust, with a lead plaintiff deadline of May 26, 2026.
- Pinterest Revenue Decline: Pinterest, Inc. (NYSE:PINS) faces a class action lawsuit for not disclosing risks of declining advertising revenues, with investor losses from February 7, 2025, to February 12, 2026, possibly leading to company restructuring, and a lead plaintiff deadline of May 29, 2026.
- New Era Energy Fraud Allegations: New Era Energy & Digital, Inc. (NASDAQ:NUAI) is being sued for falsely reporting progress on its Texas data center project and involvement in fraudulent schemes, with investor losses from November 6, 2024, to December 29, 2025, potentially affecting financial stability, and a lead plaintiff deadline of June 1, 2026.
See More
ImmunityBio Shareholder Files Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead biologic product, ANKTIVA, which may have led to investor losses.
- Lawsuit Details: Investors who acquired ImmunityBio shares during the specified period and suffered losses can file to serve as lead plaintiff by May 26, 2026, allowing them to represent other class members in the litigation and protect their interests.
- Fee Arrangement: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its expertise and influence in securities litigation.
See More
ImmunityBio Plans Expansion in Turkey Amid AI Manufacturing Advances
- Global Expansion Plans: Founder Patrick Soon-Shiong hinted at ImmunityBio's global expansion, particularly in Turkey, indicating an acceleration of its international commercialization strategy, despite a 5% decline in stock price to $8.11 on Monday.
- AI Manufacturing Robot Nears Completion: The company's AI-driven NK cell manufacturing robot, internally called “Leonardo,” is nearing completion and is expected to mass-produce natural killer cells, significantly enhancing ImmunityBio's production capabilities and competitive position in cancer immunotherapy.
- International Market Dynamics: Soon-Shiong's inspection of the manufacturing robot in Italy coincides with ImmunityBio securing approvals for its immunotherapy candidate Anktiva in multiple countries, showcasing the company's expansion momentum in the Middle East and North Africa, which boosts investor confidence in its international growth.
- Ongoing FDA Review: ImmunityBio's Anktiva is under FDA review for its supplemental biologics license application, with long-term data showing that 58.2% of patients remained cancer-free after 12 months, which could drive further development in the U.S. market.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding its immunotherapy Anktiva, with the class period spanning from January 19, 2026, to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that promotional claims made in a podcast and TV ad about Anktiva were false or misleading, resulting in a more than 21% drop in the company's stock price that day, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging those who suffered significant losses during the class period to submit their losses for potential inclusion in the class action.
- Public Health Impact: The FDA warned that the pervasive misleading efficacy claims across various promotional materials could pose serious public health risks, as they grossly misrepresent the benefits of Anktiva, raising concerns about the company's accountability and transparency.
See More
